GSK3395879
GSK3395879 is a TRPV4 antagonist that acts on hTRPV4 with an IC50 of 1 nM. GSK3395879 blocks agonist-induced TRPV4-mediated Ca2+ mobilization. GSK3395879 inhibits rat pulmonary edema induced by the TRPV4 agonist GSK1016790A (HY-19608). GSK3395879 can be used in research related to heart failure.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- CAS No.: 2215852-91-6
- Formule: C20H15F4N3O5S
- Masse moléculaire:485.41
-
Stockage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Activité biologique
-
Chemical Information
- Protocole
- Pureté et documentation
- Références
-
Help & FAQs
Activité biologique
Description
IC50 & Target
[1]|
hTRPV4 1 nM (IC50) |
In Vitro
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Sprague-Dawley rats (Male)[1]
-
Dosage:0.03, 0.08, and 0.23 mg/kg (i.v. bolus loading dose); 0.6, 1.7, and 5.1 μg/kg/min (continuous i.v. infusion)
-
Administration:i.v. bolus followed by continuous i.v. infusion; 60 min
-
Result:Inhibited the GSK1016790A-induced decrease in MAP and increase in LW/BW ratio in a dose-dependent manner.
Achieved full inhibition of the GSK1016790A-induced decrease in MAP and increase in LW/BW at an infusion dose of 5.1 μg/kg/min.
Chemical Information
-
CAS No. 2215852-91-6
-
Masse moléculaire 485.41
-
Formule C20H15F4N3O5S
-
SMILES
FC1=C(C#N)C=CC(O[C@@H]2[C@@](CO)(O)CN(S(C3=C(C#N)C=C(C(F)(F)F)C=C3)(=O)=O)C2)=C1
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
Références
[1]. Brnardic EJ, et al. Discovery of Pyrrolidine Sulfonamides as Selective and Orally Bioavailable Antagonists of Transient Receptor Potential Vanilloid-4 (TRPV4). Journal of medicinal chemistry. 2018 Nov 08;61(21):9738-9755. [Content Brief]
[2]. Nilsson M, et al. TRPV4: A Promising Therapeutic Target Ion Channel─Discovery of Ultrapotent Selective Antagonists. Journal of medicinal chemistry. 2026 Jul 23;69(14):16926-16948. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
GSK3395879 Related Classifications
HY-112202 Related Classifications
Powered by Bioz